SG11201905259SA - Preferred pairing of antibody domains - Google Patents
Preferred pairing of antibody domainsInfo
- Publication number
- SG11201905259SA SG11201905259SA SG11201905259SA SG11201905259SA SG11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibody
- domain
- domains
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17154388 | 2017-02-02 | ||
| PCT/EP2018/052624 WO2018141894A1 (en) | 2017-02-02 | 2018-02-02 | Preferred pairing of antibody domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201905259SA true SG11201905259SA (en) | 2019-08-27 |
Family
ID=57965749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201905259SA SG11201905259SA (en) | 2017-02-02 | 2018-02-02 | Preferred pairing of antibody domains |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190352429A1 (he) |
| EP (1) | EP3577137A1 (he) |
| JP (1) | JP7123063B2 (he) |
| KR (1) | KR20190113870A (he) |
| CN (1) | CN110382537B (he) |
| AU (1) | AU2018214208A1 (he) |
| BR (1) | BR112019013648A2 (he) |
| CA (1) | CA3050988A1 (he) |
| IL (1) | IL268401A (he) |
| MX (1) | MX2019007984A (he) |
| SG (1) | SG11201905259SA (he) |
| WO (1) | WO2018141894A1 (he) |
| ZA (1) | ZA201903796B (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116396393A (zh) | 2015-10-08 | 2023-07-07 | 酵活英属哥伦比亚省公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU777192B2 (en) * | 1994-05-27 | 2004-10-07 | Ariad Gene Therapeutics, Inc. | Immunosuppressant target proteins |
| CA2872136C (en) * | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
| SI1713503T1 (sl) * | 2004-02-10 | 2013-12-31 | The Regents Of The University Of Colorado, A Body Corporate | Inhibicija faktorja B, alternativna komplementa pot in relevantni postopki |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| EP2526967A1 (en) | 2007-07-17 | 2012-11-28 | Merck Patent GmbH | Engineered anti-alpha v-integrin hybrid antibodies |
| CN101348475B (zh) * | 2007-07-20 | 2011-03-30 | 重庆人本药物研究院 | 一种奥利司他合成方法、中间体化合物及其制备方法 |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| PT2773671T (pt) * | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
| EP2867253B1 (en) * | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP2970435B1 (en) | 2013-03-15 | 2020-08-12 | Eli Lilly and Company | Methods for producing fabs and bi-specific antibodies |
| US10982008B2 (en) | 2014-12-05 | 2021-04-20 | Merck Patent Gmbh | Domain-exchanged antibody |
-
2018
- 2018-02-02 EP EP18704923.4A patent/EP3577137A1/en active Pending
- 2018-02-02 MX MX2019007984A patent/MX2019007984A/es unknown
- 2018-02-02 KR KR1020197025298A patent/KR20190113870A/ko not_active Application Discontinuation
- 2018-02-02 BR BR112019013648A patent/BR112019013648A2/pt unknown
- 2018-02-02 WO PCT/EP2018/052624 patent/WO2018141894A1/en unknown
- 2018-02-02 AU AU2018214208A patent/AU2018214208A1/en active Pending
- 2018-02-02 SG SG11201905259SA patent/SG11201905259SA/en unknown
- 2018-02-02 JP JP2019541726A patent/JP7123063B2/ja active Active
- 2018-02-02 CA CA3050988A patent/CA3050988A1/en active Pending
- 2018-02-02 US US16/476,380 patent/US20190352429A1/en not_active Abandoned
- 2018-02-02 CN CN201880009856.1A patent/CN110382537B/zh active Active
-
2019
- 2019-06-12 ZA ZA2019/03796A patent/ZA201903796B/en unknown
- 2019-07-31 IL IL268401A patent/IL268401A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110382537A (zh) | 2019-10-25 |
| CN110382537B (zh) | 2023-07-25 |
| CA3050988A1 (en) | 2018-08-09 |
| WO2018141894A1 (en) | 2018-08-09 |
| RU2019119391A (ru) | 2021-03-02 |
| ZA201903796B (en) | 2022-11-30 |
| US20190352429A1 (en) | 2019-11-21 |
| JP2020505929A (ja) | 2020-02-27 |
| KR20190113870A (ko) | 2019-10-08 |
| JP7123063B2 (ja) | 2022-08-22 |
| AU2018214208A1 (en) | 2019-07-11 |
| EP3577137A1 (en) | 2019-12-11 |
| BR112019013648A2 (pt) | 2020-01-21 |
| IL268401A (he) | 2019-09-26 |
| MX2019007984A (es) | 2019-10-15 |
| RU2019119391A3 (he) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408056YA (en) | Fire suppression systems, devices, and methods | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations |